Sean Laaman
Stock Analyst at Morgan Stanley
(3.72)
# 692
Out of 5,174 analysts
26
Total ratings
61.9%
Success rate
6.27%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $11.56 | +176.82% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $69.09 | +41.84% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $41.25 | +18.79% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $157.15 | +29.81% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $6.20 | +93.55% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | - | - | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $17.13 | +98.48% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $59.11 | +94.55% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $225.75 | +34.66% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $271.09 | +41.28% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.08 | -27.88% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $62.24 | +7.65% | 1 | Feb 14, 2025 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $11.56
Upside: +176.82%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $69.09
Upside: +41.84%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $41.25
Upside: +18.79%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $157.15
Upside: +29.81%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $6.20
Upside: +93.55%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: -
Upside: -
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.13
Upside: +98.48%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $59.11
Upside: +94.55%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $225.75
Upside: +34.66%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $271.09
Upside: +41.28%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.08
Upside: -27.88%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $62.24
Upside: +7.65%